EGFR and non-small cell lung carcinoma: We prospectively collected blood samples from four patients with EGFR-mutated NSCLC at baseline and 8 weeks after EGFR-TKI treatment and measured the levels of T790M mutations and C-MET expression in plasma ctDNA using the nanowire-based colorimetric assay (Figure 6).